Medihaler Ergotamine Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

medihaler ergotamine

inova pharmaceuticals (new zealand) limited - ergotamine tartrate 0.36mg - aerosol inhaler, metered dose - 0.36 mg/dose - active: ergotamine tartrate 0.36mg

DROMELATE- dihydroergotamine mesylate injection, solution Spojené štáty - angličtina - NLM (National Library of Medicine)

dromelate- dihydroergotamine mesylate injection, solution

it3 medical llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp 3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp 3a4 inhibitors) dihydroergotamine mesylate injection, usp should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant angina. (see

TRUDHESA- dihydroergotamine mesylate spray, metered Spojené štáty - angličtina - NLM (National Library of Medicine)

trudhesa- dihydroergotamine mesylate spray, metered

impel pharmaceuticals inc. - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - trudhesa is indicated for the acute treatment of migraine with or without aura in adults. limitations of use trudhesa is not indicated for the preventive treatment of migraine. trudhesa is not indicated for the management of hemiplegic or basilar migraine. trudhesa is contraindicated in patients: - with concomitant use of strong cyp3a4 inhibitors, such as protease inhibitors (e.g., ritonavir, nelfinavir, or indinavir), macrolide antibiotics (e.g., erythromycin or clarithromycin), and antifungals (ketoconazole or itraconazole) [see warnings and precautions (5.1) and drug interactions (7.1)] - with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including prinzmetal's variant angina [see warnings and precautions (5.4)] - with uncontrolled hypertension [see warnings and precautions (5.5)] - with peripheral arterial disease - with sepsis - following vascular surge

ERGOMAR SUBLINGUAL- ergotamine tartrate tablet Spojené štáty - angličtina - NLM (National Library of Medicine)

ergomar sublingual- ergotamine tartrate tablet

tersera therapeutics, llc - ergotamine tartrate (unii: mru5xh3b48) (ergotamine - unii:pr834q503t) - ergomar® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called "histaminic cephalalgia". coadministration of ergotamine with potent cyp 3a4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see precautions: drug interactions ), with some cases resulting in amputation. there have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine was coadministered, at least one resulting in death. because of the increased risk for ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of cyp 3a4 (e.g., ketoconazole, itraconazole) (see warnings: cyp 3a4 inhibitors ). ergomar® sublingual tablets may cause fetal harm when administered to pregnant women. ergomar® subli

BELLERGAL TAB TABLET Kanada - angličtina - Health Canada

bellergal tab tablet

sandoz canada inc - belladonna; ergotamine (ergotamine tartrate); phenobarbital - tablet - .1mg; .3mg; 20mg - belladonna .1mg; ergotamine (ergotamine tartrate) .3mg; phenobarbital 20mg - antimuscarinics antispasmodics

Cafergot 1 mg - 100 mg tabl. Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

cafergot 1 mg - 100 mg tabl.

amdipharm ltd. - ergotamine tartrate 1 mg; caffeine 100 mg - tablet - 1 mg - 100 mg - ergotamine tartrate 1 mg; caffeine 100 mg - ergotamine, combinations excl. psycholeptics; n02ca72 ergotamine, combinations with psycholeptics

Diergo Spray 4 mg/ml nas. spray sol. spray cont. Belgicko - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

diergo spray 4 mg/ml nas. spray sol. spray cont.

amdipharm ltd. - dihydroergotamine mesilate 4 mg/ml - nasal spray, solution - 4 mg/ml - dihydroergotamine mesilate 4 mg/ml - dihydroergotamine

CAFERGOT TAB TABLET Kanada - angličtina - Health Canada

cafergot tab tablet

novartis pharmaceuticals canada inc - ergotamine tartrate; caffeine - tablet - 1mg; 100mg - ergotamine tartrate 1mg; caffeine 100mg - sympatholytic (adrenergic blocking) agents

Bellergal Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bellergal

novartis new zealand ltd - atropa belladonna 0.1mg; ergotamine tartrate 0.3mg; phenobarbital 20mg - tablet - 0.1mg/0.3mg/20mg - active: atropa belladonna 0.1mg ergotamine tartrate 0.3mg phenobarbital 20mg